The United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee is holding a review of United States-based Bristol-Myers Squibb's and Acceleron Pharmaceuticals supplemental Biologics License Application (sBLA) for the use of Reblozyl (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at its meeting on 18 December 2019, it was reported yesterday.
The company is seeking approval of the product, an erythroid maturation agent representing a new class of therapy, intended for the treatment of adult patients with very low- to intermediate-risk MDS -associated anaemia who have ring sideroblasts and require red blood cell transfusions.
Presently, the product is being reviewed by the US FDA for an indication in patients with MDS and it has Prescription Drug User Fee Act or target action, date of 4 April 2020 for completion of the review.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT